Cipla Ltd - Stock Valuation and Financial Performance

BSE: 500087 | NSE: CIPLA | Pharmaceuticals & Drugs | Large Cap

Cipla Share Price

1,398.85 -0.50 -0.04%
as on 18-May'24 11:24

DeciZen - make an informed investing decision on Cipla

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Semi Strong

Cipla stock performance -

mw4me loader
P/E Ratio (CD):
Market Cap:
1,12,989.9 Cr.
52-wk low:
52-wk high:

Is Cipla Ltd an attractive stock to invest in?

1. Is Cipla Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Cipla Ltd is a good quality company.

2. Is Cipla Ltd undervalued or overvalued?

The key valuation ratios of Cipla Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Cipla Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Cipla Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Cipla:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Cipla Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 13.2%10.2%9.3%6%7.9%7.5%7.9%12.5%11.8%11.8%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 10,17311,34513,59514,39415,15616,36217,13219,16021,76322,75325,447
Sales YoY Gr.-11.5%19.8%5.9%5.3%8%4.7%11.8%13.6%4.6%-
Adj EPS 16.313.715.411.416.516.417.129.13032.751
YoY Gr.--15.8%12.3%-26.4%45.1%-0.2%3.9%70.4%3.2%8.9%-
BVPS (₹) 124.8133.4142.2155.2175.9185.6194.9226.7257.8289.2330.8
Adj Net
Cash Flow from Ops. 1,5631,1731,7412,3821,4631,6913,0683,7553,3263,238-
Debt/CF from Ops. 0.81.531.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.4%8.5%9.9%4.6%
Adj EPS 8%14.7%24.2%8.9%
Share Price 13.7% 20.8% 16.5% 53%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 16.50%

Net Profit is growing at healthy rate in last 3 years 24.15%

Sales growth is good in last 4 quarters at 13.30%

Sales growth has been subdued in last 3 years 9.92%

Latest Financials - Cipla Ltd.

Standalone Consolidated
TTM EPS (₹) 46 51
TTM Sales (₹ Cr.) 14,441 25,447
BVPS (₹.) 346.5 330.8
Reserves (₹ Cr.) 27,812 26,545
P/BV 4.04 4.23
PE 30.42 27.41
From the Market
52 Week Low / High (₹) 911.80 / 1519.00
All Time Low / High (₹) 2.22 / 1519.00
Market Cap (₹ Cr.) 1,12,990
Equity (₹ Cr.) 161.5
Face Value (₹) 2
Industry PE 47.9

Management X-Ray of Cipla:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Cipla

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 8,0409,18411,11511,91912,32913,26513,95114,91117,25117,763
Manufacturing Costs8639651,2691,4451,5191,6201,6991,5151,7841,944
Material Costs3,8754,2715,0905,3175,4385,7845,9917,3528,4968,252
Employee Cost 1,5431,9682,4342,6342,6902,8573,0273,2523,5303,830
Other Costs 1,7601,9802,3222,5232,6813,0043,2332,7933,4423,737
Operating Profit 2,1332,1622,4802,4762,8263,0973,1814,2494,5124,990
Operating Profit Margin (%) 21.0%19.1%18.2%17.2%18.6%18.9%18.6%22.2%20.7%21.9%
Other Income 265166208229358477369270322512
Interest 146168207159114168197161106110
Depreciation 3735057541,3231,3231,3261,1751,0681,0521,172
Exceptional Items 0000-78000-182-182
Profit Before Tax 1,8801,6541,7271,2221,6692,0792,1783,2903,4934,038
Tax 4634003321802505706318899341,203
Profit After Tax 1,4171,2541,3951,0421,4191,5101,5472,4012,5592,835
PAT Margin (%) 13.9%11.1%10.3%7.2%9.4%9.2%9.0%12.5%11.8%12.5%
Adjusted EPS (₹)17.314.716.912.517.519.019.229.831.234.7
Dividend Payout Ratio (%)12%14%12%16%17%16%21%17%16%24%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 10,02910,71811,42712,48214,16314,95515,71018,28420,79823,346
Share Capital 161161161161161161161161161161
Reserves 9,86810,55811,26612,32114,00214,79415,54918,12320,63623,185
Minority Interest50180350438352332294259276306
Long Term Debt3183092223,6453,6623,8302,3691,2034160
Short Term Debt9061,3924,970467436486447335393188
Trade Payables9801,4521,4761,5712,1191,9482,2822,0672,5082,457
Others Liabilities 2,4103,2282,6052,2651,9402,2102,3202,6892,2612,710
Total Liabilities 14,69217,28121,04920,86922,67323,76223,42324,83726,65229,007

Fixed Assets

Gross Block8,6769,56210,16811,35312,96013,79014,91415,64716,96817,205
Accumulated Depreciation2,1802,7327991,6103,0114,2345,3096,2177,3117,995
Net Fixed Assets6,4966,8309,3689,7439,9499,5579,6049,4309,6589,210
CWIP 4425812,0611,6839816768259697661,093
Investments 7096397589731,2592,5541,4712,7102,5513,662
Trade Receivables1,6391,9982,3562,5633,1024,1513,8913,4463,4244,057
Cash Equivalents 1765648716249666191,0041,4011,9281,565
Others Assets2,3352,8891,8271,7972,3712,2412,2502,2122,9754,263
Total Assets 14,69217,28121,04920,86922,67323,76223,42324,83726,65229,007

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 1,5631,1731,7412,3821,4631,6913,0683,7553,3263,238
PBT 1,8801,6541,7271,2221,6692,0792,1783,2903,6754,221
Adjustment 5536309511,3741,2941,2691,3661,131967878
Changes in Working Capital -561-719-429235-778-1064373372-177-559
Tax Paid -308-392-508-450-722-593-848-1,037-1,140-1,302
Cash Flow From Investing Activity -1,250-941-4,523-1,310-854-1,669104-2,387-1,872-2,389
Capex -567-626-1,053-1,098-739-504-986-791-681-1,136
Net Investments 1,803-380-64-282-1,0641,029-1,675153-913
Others -2,486-278-3,470-148167-1016180-1,343-340
Cash Flow From Financing Activity -2661653,104-1,326-385-349-2,949-1,240-1,600-958
Net Proceeds from Shares 012312000000
Net Proceeds from Borrowing 1567-663,420-3-58-1,736-951-1,041-44
Interest Paid -121-167-161-159-118-159-164-121-76-65
Dividend Paid -161-161-159-161-161-242-5640-403-404
Others -1404743,488-4,438-104109-485-168-80-446
Net Cash Flow 48397322-254223-326224129-146-109
ROE (%)14.8912.112.618.7210.6510.3710.0914.1313.112.85
ROCE (%)19.0515.3313.248.2810.211.9412.5317.8517.2418.19
Asset Turnover Ratio0.760.720.720.
PAT to CFO Conversion(x)1.10.941.
Working Capital Days
Receivable Days59585861685554474244
Inventory Days9410610091906156586262
Payable Days8510410510512412812910898110

Cipla Ltd Stock News

Cipla Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Cipla on 18-May-2024 11:24 is ₹1,398.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-May-2024 11:24 the market cap of Cipla stood at ₹1,12,989.9.
The latest P/E ratio of Cipla as of 18-May-2024 11:24 is 30.42.
The latest P/B ratio of Cipla as of 18-May-2024 11:24 is 4.04.
The 52-week high of Cipla is ₹1,519 and the 52-week low is ₹911.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cipla is ₹14,441 ( Cr.) .

About Cipla Ltd

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.


  • Generics and branded generics
  • Specialty
  • Consumer health



  • Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
  • Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
  • Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
  • Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.


  • Cipla won the Global L&D Team of the Year Award
  • Brand, Azee bagged the Marketing Excellence Award in 2014
  • Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
  • Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs


  • Won the Award for Excellence in Rural Reach at India Pharma Awards
  • Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
  • Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
  • Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
  • ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015


  • The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
  • Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
  • Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
  • Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
  • Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
  • Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners


  • Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
  • ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
  • Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017


  • India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
  • Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
  • SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
  • Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
  • Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
  • India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
  • Indian Digital Awards (IDA) for Excellence in Digital Publishing
  • ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets


  • Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
  • Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
  • 'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
  • ‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
  • Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019


  • Cipla Sri Lanka is Great Place to Work Certified
  • Cipla is Great Place to Work Certified
  • ‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
  • Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
  • What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
  • The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report


  • 1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
  • 1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
  • 1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
  • 1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
  • 1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
  • 1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
  • 2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
  • 2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
  • 2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
  • 2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
  • 2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
  • 2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.